Clinical Cancer Research Prevention Award Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanghani, S. P.
Right arrow Articles by Bosron, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanghani, S. P.
Right arrow Articles by Bosron, W. F.
Clinical Cancer Research Vol. 9, 4983-4991, October 15, 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Carboxylesterases Expressed in Human Colon Tumor Tissue and Their Role in CPT-11 Hydrolysis

Sonal P. Sanghani, Sara K. Quinney, Tyler B. Fredenburg, Zejin Sun, Wilhelmina I. Davis, Daryl J. Murry, Oscar W. Cummings, David E. Seitz and William F. Bosron1

Departments of Biochemistry and Molecular Biology [S. P. S., T. B. F., Z. S., W. I. D., W. F. B.], Pathology [O. W. C.], Hematology and Oncology [D. E. S.], Indiana University School of Medicine, Indianapolis, Indiana 46202; Department of Pharmacy Practice, Purdue University, Indianapolis, Indiana 46202 [S. K. Q., D. J. M.]

Purpose: The purpose is to develop new analytical methods to study the expression profile of CPT-11 carboxylesterases and topoisomerase I in colon tumor samples and understand the impact of their expression on CPT-11 metabolism in chemotherapy.

Experimental Design: We investigated 24 colon tumors for expression of carboxylesterases CES1A1, CES2, CES3, hBr-3, and topoisomerase I genes by real-time PCR and correlated the gene expression with activity assays. The relative abundance of the carboxylesterase isoenzymes and topoisomerase I genes was determined by real-time PCR. Activity assays performed on colon tumor extracts included CPT-11 hydrolase, 4-methylumbelliferyl acetate hydrolase, and topoisomerase I activity assays. Additionally, nondenaturing activity gel electrophoresis with activity staining showed the distribution of carboxylesterases.

Results: We detect the expression of CES1A1, CES2, and CES3 carboxylesterase genes in human colon tumors. We were unable to detect the hBr-3 (also called hCE-3) in human liver, colon, or brain. We find large interindividual variation, >=150-fold, for both CES1A1 and CES3 genes, 23-fold for CES2, and 66-fold for topoisomerase I. Only CES2 gene expression correlated with the carboxylesterase activity assays (P < 0.01) with CPT-11 and 4-methylumbelliferyl acetate as substrates. Nondenaturing activity gel electrophoresis showed that CES2 was the most predominant activity. Topoisomerase I gene expression significantly correlated with topoisomerase I activity (P < 0.01) in the colon tumors, but interindividual variation was very high.

Conclusions: We conclude that CES2 is the most abundant carboxylesterase in colon tumors that is responsible for CPT-11 hydrolysis. This pilot study reinforces the hypothesis that there is a large interindividual variation in expression of carboxylesterases that may contribute to variation in therapeutic outcome and/or toxicity of CPT-11 therapy for colon cancer.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
C. Jewell, C. Ackermann, N. A. Payne, G. Fate, R. Voorman, and F. M. Williams
Specificity of Procaine and Ester Hydrolysis by Human, Minipig, and Rat Skin and Liver
Drug Metab. Dispos., November 1, 2007; 35(11): 2015 - 2022.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. A. Schiel, S.-l. Green, W. I. Davis, P. C. Sanghani, W. F. Bosron, and S. P. Sanghani
Expression and Characterization of a Human Carboxylesterase 2 Splice Variant
J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 94 - 101.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Imai, M. Imoto, H. Sakamoto, and M. Hashimoto
IDENTIFICATION OF ESTERASES EXPRESSED IN CACO-2 CELLS AND EFFECTS OF THEIR HYDROLYZING ACTIVITY IN PREDICTING HUMAN INTESTINAL ABSORPTION
Drug Metab. Dispos., August 1, 2005; 33(8): 1185 - 1190.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. K. Quinney, S. P. Sanghani, W. I. Davis, T. D. Hurley, Z. Sun, D. J. Murry, and W. F. Bosron
Hydrolysis of Capecitabine to 5'-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide
J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1011 - 1016.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. Tabata, M. Katoh, S. Tokudome, M. Nakajima, and T. Yokoi
IDENTIFICATION OF THE CYTOSOLIC CARBOXYLESTERASE CATALYZING THE 5'-DEOXY-5-FLUOROCYTIDINE FORMATION FROM CAPECITABINE IN HUMAN LIVER
Drug Metab. Dispos., October 1, 2004; 32(10): 1103 - 1110.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
Z. Sun, D. J. Murry, S. P. Sanghani, W. I. Davis, N. Y. Kedishvili, Q. Zou, T. D. Hurley, and W. F. Bosron
Methylphenidate Is Stereoselectively Hydrolyzed by Human Carboxylesterase CES1A1
J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 469 - 476.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. P. Sanghani, S. K. Quinney, T. B. Fredenburg, W. I. Davis, D. J. Murry, and W. F. Bosron
HYDROLYSIS OF IRINOTECAN AND ITS OXIDATIVE METABOLITES, 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO] CARBONYLOXYCAMPTOTHECIN AND 7-ETHYL-10-[4-(1-PIPERIDINO)-1-AMINO]-CARBONYLOXYCAMPTOTHECIN, BY HUMAN CARBOXYLESTERASES CES1A1, CES2, AND A NEWLY EXPRESSED CARBOXYLESTERASE ISOENZYME, CES3
Drug Metab. Dispos., May 1, 2004; 32(5): 505 - 511.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.